Maher K Gandhi

List of Publications by Year
in descending order

139	5,652	76326	82547
papers	citations	40 h-index	72 g-index

141	141	141	7982
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood, 2007, 110, 1123-1131.	1.4	584
2	Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infectious Diseases, The, 2004, 4, 725-738.	9.1	486
3	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 2015, 125, 3679-3687.	1.4	270
4	Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood, 2018, 131, 1809-1819.	1.4	231
5	Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigenâ€“specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood, 2006, 108, 2280-2289.	1.4	215
6	Identification of Naive or Antigen-Experienced Human CD8+ T Cells by Expression of Costimulation and Chemokine Receptors: Analysis of the Human Cytomegalovirus-Specific CD8+ T Cell Response. Journal of Immunology, 2002, 168, 5455-5464.	0.8	189
7	Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era. American Journal of Transplantation, 2013, 13, 1512-1522.	4.7	150
8	Immunodeficiency-associated lymphomas. Blood Reviews, 2008, 22, 261-281.	5.7	149
9	Galectin-1 mediated suppression of Epstein-Barr virusâ€“specific T-cell immunity in classic Hodgkin lymphoma. Blood, 2007, 110, 1326-1329.	1.4	145
10	Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarker. Nature Communications, 2018, 9, 4915.	12.8	135
11	EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. Journal of Clinical Investigation, 2012, 122, 1487-1502.	8.2	132
12	Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma. Clinical Cancer Research, 2006, 12, 460-464.	7.0	129
13	Epsteinâ€“Barr virusâ€associated Hodgkin's lymphoma. British Journal of Haematology, 2004, 125, 267-281.	2.5	123
14	Epsteinâ€“Barr Virus-Related Post-Transplant Lymphoproliferative Disorders: Pathogenetic Insights for Targeted Therapy. American Journal of Transplantation, 2011, 11, 888-895.	4.7	117
15	Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma. Clinical Cancer Research, 2014, 20, 253-264.	7.0	117
16	Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma. Clinical Cancer Research, 2013, 19, 731-742.	7.0	91
17	Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration. Journal of Clinical Oncology, 2019, 37, 3300-3309.	1.6	83
18	Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplantation, 2001, 28, 775-781.	2.4	78

#	Article	IF	Citations
19	Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematology,the, 2015, 2, e445-e455.	4.6	74
20	CD4⁺ Tumor infiltrating lymphocytes are prognostic and independent of Râ€IPI in patients with DLBCL receiving Râ€CHOP chemoâ€immunotherapy. American Journal of Hematology, 2013, 88, 273-276.	4.1	71
21	Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment. Blood, 2020, 136, 3004-3017.	1.4	71
22	Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: longâ€term followâ€up of a prospective study. British Journal of Haematology, 2003, 121, 462-468.	2.5	68
23	LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Advances, 2020, 4, 1367-1377.	5.2	66
24	Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. Blood, 2010, 116, 2245-2252.	1.4	65
25	The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma. Clinical Cancer Research, 2017, 23, 1820-1828.	7.0	65
26	Functional Reversion of Antigen-Specific CD8+ T Cells from Patients with Hodgkin Lymphoma following In Vitro Stimulation with Recombinant Polyepitope. Journal of Immunology, 2006, 177, 4897-4906.	0.8	63
27	Technology Insight: applications of emerging immunotherapeutic strategies for Epsteinâ€“Barr virus-associated malignancies. Nature Clinical Practice Oncology, 2005, 2, 138-149.	4.3	61
28	Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation. Blood, 2003, 102, 3427-3438.	1.4	59
29	EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood, 2021, 137, 1468-1477.	1.4	59
30	The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplantation, 1999, 23, 9-13.	2.4	58
31	Immunity, Homing and Efficacy of Allogeneic Adoptive Immunotherapy for Posttransplant Lymphoproliferative Disorders. American Journal of Transplantation, 2007, 7, 1293-1299.	4.7	58
32	Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica, 2017, 102, 356-363.	3.5	53
33	Biology and therapy of primary mediastinal Bâ€cell lymphoma: current status and future directions. British Journal of Haematology, 2019, 185, 25-41.	2.5	51
34	A Comprehensive Analysis of the Cellular and EBV-Specific MicroRNAome in Primary CNS PTLD Identifies Different Patterns Among EBV-Associated Tumors. American Journal of Transplantation, 2014, 14, 2577-2587.	4.7	50
35	Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma. Cell Reports, 2020, 31, 107522.	6.4	50
36	Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of nonâ€Hodgkin's lymphoma. Genes Chromosomes and Cancer, 2011, 50, 313-326.	2.8	45

#	Article	IF	Citations
37	EBV microRNA-BHRF1-2-5p targets the 3â€²UTR of immune checkpoint ligands PD-L1 and PD-L2. Blood, 2019, 134, 2261-2270.	1.4	44
38	A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study. Bone Marrow Transplantation, 1998, 22, 273-276.	2.4	43
39	Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica, 2022, 107, 690-701.	3.5	43
40	The tumour microenvironment is immunoâ€tolerogenic and a principal determinant of patient outcome in EBVâ€positive diffuse large Bâ€cell lymphoma. European Journal of Haematology, 2019, 103, 200-207.	2.2	42
41	A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations. British Journal of Haematology, 2000, 110, 599-604.	2.5	40
42	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Advances, 2019, 3, 2013-2021.	5.2	40
43	Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies. Blood Reviews, 2015, 29, 405-415.	5.7	38
44	The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma. Clinical and Experimental Immunology, 2016, 183, 206-220.	2.6	38
45	Follicular lymphoma: time for a re-think?. Blood Reviews, 2005, 19, 165-178.	5.7	36
46	Dielectrophoretic Microfluidic Chip Enables Single-Cell Measurements for Multidrug Resistance in Heterogeneous Acute Myeloid Leukemia Patient Samples. Analytical Chemistry, 2016, 88, 5680-5688.	6.5	35
47	Epsteinâ€“Barr virus-associated lymphomas. Expert Review of Anti-Infective Therapy, 2006, 4, 77-89.	4.4	34
48	Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. British Journal of Haematology, 2021, 192, 1049-1053.	2.5	31
49	Tumorâ€specific but not nonspecific cellâ€free circulating DNA can be used to monitor disease response in lymphoma. American Journal of Hematology, 2012, 87, 258-265.	4.1	30
50	A new prognosticator for postâ€transplant lymphoproliferative disorders after renal transplantation. British Journal of Haematology, 2008, 141, 904-907.	2.5	29
51	Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation. Blood Reviews, 2003, 17, 259-264.	5.7	28
52	A multiâ€centre, singleâ€arm, openâ€label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (Râ€<scp>ITP</scp>1000 study). British Journal of Haematology, 2014, 167, 243-251.	2.5	27
53	Targeting an adenosine-mediated â€œdonâ€™t eat me signalâ€•augments anti-lymphoma immunity by anti-CD20 monoclonal antibody. Leukemia, 2020, 34, 2708-2721.	7.2	27
54	Sodium valproate in combination with ganciclovir induces lysis of EBVâ€infected lymphoma cells without impairing EBVâ€specific Tâ€cell immunity. International Journal of Laboratory Hematology, 2010, 32, e169-74.	1.3	26

#	Article	IF	Citations
55	Relative abundance of full-length and truncated FOXP1 isoforms is associated with differential NFÎºB activity in Follicular Lymphoma. Leukemia Research, 2009, 33, 1699-1702.	0.8	25
56	Expression profiling of Epstein-Barr virus-encoded microRNAs from paraffin-embedded formalin-fixed primary Epstein-Barr virus-positive B-cell lymphoma samples. Journal of Virological Methods, 2012, 184, 46-54.	2.1	25
57	Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions. Blood Advances, 2019, 3, 1681-1694.	5.2	24
58	Homozygous <scp>FCGR3A</scp>â€158<scp>V</scp> alleles predispose to late onset neutropenia after <scp>CHOPâ€R</scp> for diffuse large <scp>B</scp>â€cell lymphoma. Internal Medicine Journal, 2012, 42, 1113-1119.	0.8	23
59	Selective accumulation of virus-specific CD8+ T cells within the peripheral blood stem cell compartment. Blood, 2009, 114, 2001-2003.	1.4	21
60	A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis. Bone Marrow Transplantation, 1999, 24, 369-375.	2.4	19
61	Highâ€resolution loss of heterozygosity screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to nonâ€hodgkin's lymphoma. Genes Chromosomes and Cancer, 2013, 52, 467-479.	2.8	19
62	A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival. Oncotarget, 2018, 9, 23620-23627.	1.8	19
63	Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes. American Journal of Blood Research, 2011, 1, 146-59.	0.6	19
64	The Epstein-Barr virus microRNA BART11-5p targets the early B-cell transcription factor EBF1. American Journal of Blood Research, 2013, 3, 210-24.	0.6	19
65	B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity. OncoImmunology, 2018, 7, e1393599.	4.6	17
66	The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms. Blood Coagulation and Fibrinolysis, 2012, 23, 45-50.	1.0	16
67	Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Advances, 2019, 3, 2804-2811.	5.2	15
68	Viruses and lymphoma. Pathology, 2005, 37, 420-433.	0.6	14
69	Epstein?Barr virus T-cell immunity despite rituximab. British Journal of Haematology, 2007, 136, 628-632.	2.5	14
70	Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphoma. Oncotarget, 2018, 9, 34644-34657.	1.8	14
71	The presence of <scp>KIR2DS5</scp> confers protection against adult immune thrombocytopenia. Tissue Antigens, 2014, 83, 154-160.	1.0	13
72	Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients. Nephrology Dialysis Transplantation, 2015, 30, 1774-1779.	0.7	13

#	Article	IF	Citations
73	Successful treatment of Epsteinâ€“Barr virusâ€“associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epsteinâ€“Barr virusâ€“specific T cells. American Journal of Transplantation, 2021, 21, 3465-3471.	4.7	13
74	Methotrexate-associated mantle-cell lymphoma in an elderly man with myasthenia gravis. Nature Clinical Practice Oncology, 2008, 5, 234-238.	4.3	10
75	High levels of BACH2 associated with lower levels of BCL2 transcript abundance in t(14;18)(q21;q34) translocation positive non-Hodgkinâ€™s lymphoma. Leukemia Research, 2009, 33, 731-734.	0.8	10
76	HLA class I associations with EBV+ post-transplant lymphoproliferative disorder. Transplant Immunology, 2015, 32, 126-130.	1.2	10
77	Correlation of T-cell immune response with spontaneous resolution and subsequent relapse of Hodgkin's lymphoma. Leukemia and Lymphoma, 2006, 47, 871-876.	1.3	8
78	A novel immunodeficiency disorder characterized by genetic amplification of interleukin 25. Genes and Immunity, 2011, 12, 663-666.	4.1	8
79	A new frontier in haematology â€“ combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug. British Journal of Clinical Pharmacology, 2014, 78, 274-281.	2.4	8
80	In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkinâ€™s lymphoma (NHL). BMC Genomics, 2014, 15, 390.	2.8	8
81	Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target. British Journal of Haematology, 2021, 195, 113-118.	2.5	8
82	Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. Blood Advances, 2021, 5, 2644-2649.	5.2	7
83	Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG). Blood, 2015, 126, 815-815.	1.4	7
84	Recent treatment advances in Hodgkin lymphoma: a concise review. Internal Medicine Journal, 2016, 46, 1364-1369.	0.8	6
85	Simple, rapid and inexpensive typing of common HLA class I alleles for immunological studies. Journal of Immunological Methods, 2019, 465, 72-76.	1.4	6
86	Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas. Blood Reviews, 2021, 50, 100832.	5.7	5
87	Epstein-Barr virus and advanced chronic lymphocytic leukemia: innocent until proven guilty?. Leukemia and Lymphoma, 2006, 47, 779-780.	1.3	4
88	Epsteinâ€“Barr virus DNA as a biomarker for Epsteinâ€“Barr virus-positive lymphomas: are we there yet?. Leukemia and Lymphoma, 2009, 50, 684-686.	1.3	4
89	Fulminant Infectious Mononucleosis and Recurrent Epsteinâ€Barr Virus Reactivation in an Adolescent. Clinical Infectious Diseases, 2010, 50, e34-e37.	5.8	4
90	Whole blood EBV-DNA: A surrogate for immune dysfunction in aggressive lymphoma?. Leukemia and Lymphoma, 2016, 57, 507-508.	1.3	4

#	Article	IF	Citations
91	The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin Lymphoma. Blood, 2018, 132, 4123-4123.	1.4	4
92	Can a blood test monitor lymphoma?. Leukemia and Lymphoma, 2010, 51, 957-959.	1.3	3
93	Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients. Immunotherapy, 2011, 3, 1441-1443.	2.0	3
94	FcÎ³-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder. Journal of Immunology Research, 2014, 2014, 1-6.	2.2	3
95	Targeted Treatment of Follicular Lymphoma. Journal of Personalized Medicine, 2021, 11, 152.	2.5	3
96	Molecular mechanisms influencing NK cell development: implications for NK cell malignancies. American Journal of Blood Research, 2011, 1, 34-45.	0.6	3
97	The use of T-cell directed cellular therapies in Australia. Cytotherapy, 2007, 9, 222-224.	0.7	2
98	Genetic aberrations of NLRC5 are associated with downregulated MHCâ€Ⅰ antigen presentation and impaired Tâ€•cell immunity in follicular lymphoma. EJHaem, 2020, 1, 517-526.	1.0	2
99	Intra-Tumoral CD8+ T-Cells in Follicular Lymphoma Contain Large Clonal Expansions That Are Amenable to Dual-Checkpoint Blockade. Blood, 2019, 134, 2793-2793.	1.4	2
100	A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+ Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 918-918.	1.4	2
101	Validation of Elevated Blood Soluble PD-L1 As an Independent Prognostic Marker in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2014, 124, 2998-2998.	1.4	2
102	The Tumor Microenvironment Is Independently Prognostic of Conventional and Clinicogenetic Risk Models in Follicular Lymphoma. Blood, 2017, 130, 728-728.	1.4	2
103	Neoantigens â€“ the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders. Blood Reviews, 2022, 56, 100969.	5.7	2
104	A case of transfusion-acquired hepatitis C. International Journal of Laboratory Hematology, 2008, 15, 141-144.	0.2	1
105	What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century?. Medical Journal of Australia, 2009, 190, 461-461.	1.7	1
106	The role of Epsteinâ€“Barr virus in Richter syndrome. British Journal of Haematology, 2009, 144, 613-613.	2.5	1
107	Broad-spectrum immunosuppression by classless monocytes in non-Hodgkinâ€™s lymphoma. Immunotherapy, 2011, 3, 723-726.	2.0	1
108	Back to basics: the complete blood cell count adds to the ability of immunohistochemistry in diffuse large B-cell lymphoma prognosis. Leukemia and Lymphoma, 2012, 53, 2097-2098.	1.3	1

#	Article	IF	Citations
109	Reply to M. Sorigue. Journal of Clinical Oncology, 2020, 38, 648-649.	1.6	1
110	<scp>Riskâ€adapted</scp> therapy in follicular lymphoma: Is it time to <scp>â€œFLEXâ€</scp>?. American Journal of Hematology, 2020, 95, 1454-1456.	4.1	1
111	DA-EPOCH-R in Burkitt Lymphoma: Is It Enough for High-Risk Disease?. Journal of Clinical Oncology, 2020, 38, 3722-3723.	1.6	1
112	Elevated LAG-3 Expression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis. Blood, 2018, 132, 1576-1576.	1.4	1
113	Outcomes of Stage I and II Follicular Lymphoma in the Era of 18F-FDG PET-CT Staging: An International Collaborative Study from the Australian Lymphoma Alliance. Blood, 2018, 132, 4148-4148.	1.4	1
114	Neoantigens Are Typically Associated with Intact HLA Class I Presentation in Early-Stage Follicular Lymphoma. Blood, 2020, 136, 37-38.	1.4	1
115	Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6. Blood, 2011, 118, 1585-1585.	1.4	1
116	Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL,. Blood, 2011, 118, 3673-3673.	1.4	1
117	Intratumoral Tâ€cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large Bâ€cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (Râ€CHOP) chemoimmunotherapy. Clinical and Translational Immunology, 2021, 10, e1351.	3.8	1
118	A Cost-Effectiveness Analysis of Front-Line Treatment Strategies in Early Stage Follicular Lymphoma. Blood, 2020, 136, 54-55.	1.4	1
119	Regulation of clinical research. Clinical Medicine, 2005, 5, 299.1-299.	1.9	0
120	Inducing remission in drug resistant acute myeloid leukaemia with cyclosporin A. International Journal of Laboratory Hematology, 2008, 15, 219-221.	0.2	0
121	Discordant solutions to discordant problems. Blood, 2021, 137, 2857-2858.	1.4	0
122	A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. Leukemia and Lymphoma, 2021, 62, 3484-3492.	1.3	0
123	Host Genetic Mutations and Expression Analyses in PTLD. , 2021, , 39-50.		0
124	EBV MicroRNA Expression in Virus Driven B-Cell Differentiation and Lymphomagenesis.. Blood, 2009, 114, 93-93.	1.4	0
125	Loss of Heterozygosity (LOH) of PTPRJ in Non-Hodgkin`s Lymphoma (NHL). Blood, 2011, 118, 5231-5231.	1.4	0
126	A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms. Blood, 2011, 118, 1157-1157.	1.4	0

#	Article	IF	Citations
127	Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma. Blood, 2012, 120, 49-49.	1.4	0
128	Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell Lymphoma. Blood, 2012, 120, 5119-5119.	1.4	0
129	Abstract B38: FOXP1 truncated isoforms differentially regulate target genes in diffuse large B cell lymphoma.. , 2013, , .		0
130	HLA-Class I Alleles Impact Susceptibility To EBV+ Classical Hodgkin Lymphoma By Altering EBV Latent Antigen-Specific CD8+ T-Cell Immune Hierarchies. Blood, 2013, 122, 630-630.	1.4	0
131	Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant Patients. Blood, 2013, 122, 1780-1780.	1.4	0
132	Circulating Biomarkers in Hodgkin Lymphoma. , 2014, , 1-19.		0
133	Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL.. Journal of Clinical Oncology, 2014, 32, 8504-8504.	1.6	0
134	Net antitumoral immunity and the predictive power of conventional prognosticators in diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2014, 32, 8542-8542.	1.6	0
135	Serum CD163 and TARC as Circulating Biomarkers in Hodgkin Lymphoma. Biomarkers in Disease, 2015, , 955-978.	0.1	0
136	The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL). Blood, 2015, 126, 3893-3893.	1.4	0
137	The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial. Blood, 2017, 130, 825-825.	1.4	0
138	A Complicated Neighborhood: Insights into the Hodgkin Lymphoma Microenvironment. Blood, 2019, 134, SCI-8-SCI-8.	1.4	0
139	The NLPHL Tumor Microenvironment Is Markedly Enriched in the Tigit and PD-1 Signalling Axes Compared to Classical Hodgkin Lymphoma. Blood, 2021, 138, 3513-3513.	1.4	0